FDA Releases FY2025 GDUFA Research Report, Enhancing Complex Generic Drug Review
The U.S. Food and Drug Administration (FDA) has published the FY2025 GDUFA Science and Research Report for April 2026, outlining research projects and regulatory achievements supporting the development of complex generic drugs. This initiative focuses on releasing scientific evidence for biological equivalence (BE) and pharmaceutical equivalence assessments, rather than specific drug approvals or Advisory Committee (AdComm) reviews. Therefore, it should not be interpreted as direct approvals or exclusive rights granted to companies like Teva Pharmaceutical Industries (TEVA), Sandoz Group (SDZ), or Viatris (VTRS).
The FDA issued 925 Product-Specific Guidances (PSGs) in FY2025, with 49 addressing complex products, bringing the cumulative total to 2,288 as of September 30, 2025. For inhaled and nasal products, the FDA has refined the BE approach by utilizing in vitro characterization and modeling instead of comparative clinical endpoint studies. For transdermal patches, the FDA provides recommendations for adhesion, irritation, and sensitization assessments. The key benefit for complex products, such as synthetic peptides, liposomes, ophthalmic suspensions, and dry powder inhalers, is that developers can determine the necessary analyses and testing designs early in the development process.
The FDA page provides FML-branded fluorometholone ophthalmic suspension as an example, which is a commercially available ophthalmic corticosteroid that activates the glucocorticoid receptor. In the same inflammatory eye disease indication, existing marketed steroids such as prednisolone acetate and loteprednol form a therapeutic and price competition group. However, the industrial benefits of the report are broadly distributed to companies like Teva, Sandoz, Viatris, and Sun Pharmaceutical Industries, which possess complex ANDA portfolios and analytical/manufacturing capabilities, rather than being limited to specific drugs.
The FY2026 ANDA application fee is USD 358,247 per application, and the large generic applicant program fee is USD 1,918,377, effective October 1, 2025. While the high fixed costs may be a burden for small developers, the PSGs and pre-ANDA meetings serve as practical offsets by reducing the likelihood of inappropriate trial designs and repeated reviews. The U.S. generic market is projected to reach USD 154.45 billion in 2026, with generics and biosimilars accounting for 90% of prescriptions and approximately 12% of drug spending in 2024. The economic value of regulatory science lies in increasing competition in complex products, thereby improving prices and supply stability, rather than individual approvals.
Of the 925 PSGs issued in FY2025, 49 address complex products, providing researchers and development teams with more specific criteria for designing BE and quality tests for synthetic peptides, inhalers, transdermal products, and ophthalmic suspensions. From an investment perspective, in the USD 154.45 billion U.S. generic market projected for 2026, companies like Teva (TEVA), Sandoz (SDZ), and Viatris (VTRS) with complex ANDA capabilities are the primary beneficiaries of increased regulatory clarity, although this does not guarantee individual product approvals or sales. In the short term, the ANDA fee of USD 358,247 per application and manufacturing/analytical costs act as barriers to entry, favoring companies with scale and quality systems. In the medium to long term, in vitro-based BE assessments that reduce reliance on clinical trials will increase the development efficiency and supply options for complex generics that compete with existing marketed therapies such as prednisolone and loteprednol.
Source: FDA Drug Approvals (rss)
http://www.fda.gov/drugs/generic-drugs/generic-drug-research-related-guidances-reports